We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
- Authors
Kindler, Hedy L; Friberg, Gregory; Singh, Deepti A; Locker, Gershon; Nattam, Sreenivasa; Kozloff, Mark; Taber, David A; Karrison, Theodore; Dachman, Abraham; Stadler, Walter M; Vokes, Everett E
- Abstract
Vascular endothelial growth factor (VEGF) plays a key role in the biology and prognosis of pancreatic cancer. Inhibitors of VEGF suppress the growth of pancreatic cancer in preclinical models. The objectives of this phase II study were to assess the response rate and overall survival of pancreatic cancer patients who received gemcitabine with the recombinant humanized anti-VEGF monoclonal antibody bevacizumab.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Vol 23, Issue 31, p8033
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2005.01.9661